AstraZeneca, Teva Reach Patent Deal Over Entocort

Law360, New York (May 18, 2010, 12:26 PM EDT) -- AstraZeneca LP has settled its infringement claims against Teva Pharmaceuticals USA Inc. over Entocort EC, striking a deal that will let the generic-drug maker start selling its own version of the Crohn's disease treatment in the U.S. in February 2012.

The companies will seek approval for the deal through a consent judgment in the U.S. District Court for the District of Delaware, they said in separate statements Tuesday.

The settlement gives Teva an exclusive license to market a generic oral budesonide capsule on Feb. 15, 2012,...
To view the full article, register now.